These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34544970)

  • 1. Clinical Efficacy of Intracoronary Papaverine After Nicorandil Administration for Safe and Optimal Fractional Flow Reserve Measurement.
    Inoue K; Sonoda S; Naka Y; Okabe H; Setoyama K; Miura T; Anai R; Araki M; Kataoka M
    Int Heart J; 2021 Sep; 62(5):962-969. PubMed ID: 34544970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confirmation of maximal hyperemia by the incremental dose of intracoronary papaverine.
    Nakayama M; Tanaka N; Yamashita J; Iwasaki K
    Cardiovasc Interv Ther; 2020 Oct; 35(4):371-378. PubMed ID: 31939068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the risk factors for ventricular arrhythmias secondary to QT prolongation induced by papaverine injection during coronary flow reserve studies using a 4 Fr angio-catheter.
    Okabe Y; Otowa K; Mitamura Y; Murai H; Usui S; Kaneko S; Takamura M
    Heart Vessels; 2018 Nov; 33(11):1358-1364. PubMed ID: 29713819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of additional intracoronary nicorandil administration during fractional flow reserve measurement with intravenous adenosine 5'-triphosphate infusion.
    Takami H; Sonoda S; Muraoka Y; Sanuki Y; Kashiyama K; Fukuda S; Oginosawa Y; Tsuda Y; Araki M; Otsuji Y
    J Cardiol; 2017 Jan; 69(1):119-124. PubMed ID: 26947100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of increasing dose of intracoronary adenosine on peak hyperemia duration during fractional flow reserve assessment.
    Verdoia M; Erbetta R; Sagazio E; Barbieri L; Negro F; Suryapranata H; Kedhi E; De Luca G;
    Int J Cardiol; 2019 Jun; 284():16-21. PubMed ID: 30293665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and safety of intracoronary nicorandil infusion as a novel hyperemic agent for fractional flow reserve measurements.
    Kato D; Takashima H; Waseda K; Kurita A; Kuroda Y; Kosaka T; Kuhara Y; Ando H; Maeda K; Kumagai S; Sakurai S; Suzuki A; Toda Y; Watanabe A; Sato S; Fujimoto M; Mizuno T; Amano T
    Heart Vessels; 2015 Jul; 30(4):477-83. PubMed ID: 24748047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of coronary flow reserve by intracoronary administration of nicorandil: comparison with intracoronary administration of papaverine.
    Inoue F; Hashimoto T; Fujimoto S; Uemura S; Kawamoto A; Dohi K
    Heart Vessels; 1998; 13(5):229-36. PubMed ID: 10483772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of combined administration of intracoronary papaverine plus intravenous adenosine 5'-triphosphate in assessment of fractional flow reserve.
    Nishi T; Kitahara H; Iwata Y; Fujimoto Y; Nakayama T; Takahara M; Sugimoto K; Kobayashi Y
    J Cardiol; 2016 Dec; 68(6):512-516. PubMed ID: 26811149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility and Validity of Intracoronary Administration of Nicorandil Alone for the Measurement of Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis.
    Ishibuchi K; Fujii K; Otsuji S; Takiuchi S; Hasegawa K; Tamaru H; Ishii R; Yasuda S; Nakabayashi S; Yamamoto W; Kusumoto H; Taniguchi Y; Kakishita M; Shimatani Y; Higashino Y
    Circ J; 2019 Sep; 83(10):2010-2016. PubMed ID: 31413232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous nicorandil versus adenosine for fractional flow reserve measurement: a crossover, randomized study.
    Nishi T; Kitahara H; Fujimoto Y; Nakayama T; Nagashima K; Hanaoka H; Kobayashi Y
    Heart Vessels; 2018 Dec; 33(12):1570-1575. PubMed ID: 29858919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of caffeine on fractional flow reserve values measured using intravenous adenosine triphosphate.
    Nakayama M; Chikamori T; Uchiyama T; Kimura Y; Hijikata N; Ito R; Yuhara M; Sato H; Kobori Y; Yamashina A
    Cardiovasc Interv Ther; 2018 Apr; 33(2):116-124. PubMed ID: 28110424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility and safety of intracoronary nicorandil as a hyperemic agent for the measurement of fractional flow reserve.
    Chhabria R; Mehta NP; Jain N; Handa SR; Mehta AB
    Indian Heart J; 2020; 72(6):603-605. PubMed ID: 33357653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracoronary adenosine-induced ventricular arrhythmias during fractional flow reserve (FFR) measurement: case series and literature review.
    Patel HR; Shah P; Bajaj S; Virk H; Bikkina M; Shamoon F
    Cardiovasc Interv Ther; 2017 Oct; 32(4):374-380. PubMed ID: 27577946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Papaverine-induced polymorphic ventricular tachycardia during coronary flow reserve study of patients with moderate coronary artery disease.
    Nakayama M; Tanaka N; Sakoda K; Hokama Y; Hoshino K; Kimura Y; Ogawa M; Yamashita J; Kobori Y; Uchiyama T; Aizawa Y; Yamashina A
    Circ J; 2015; 79(3):530-6. PubMed ID: 25746536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation.
    Goto M; Sato M; Kitazawa H; Takahashi M; Fuse K; Saito A; Okabe M; Aizawa Y
    Intern Med; 2014; 53(15):1629-31. PubMed ID: 25088875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive value of nicorandil on ATP for further inducing hyperemia in patients with an intermediate coronary artery stenosis.
    Kobayashi Y; Okura H; Neishi Y; Higa T; Kobayashi Y; Uemura S; Yoshida K
    Coron Artery Dis; 2017 Mar; 28(2):104-109. PubMed ID: 27611876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximal hyperemia in the assessment of fractional flow reserve: intracoronary adenosine versus intracoronary sodium nitroprusside versus intravenous adenosine: the NASCI (Nitroprussiato versus Adenosina nelle Stenosi Coronariche Intermedie) study.
    Leone AM; Porto I; De Caterina AR; Basile E; Aurelio A; Gardi A; Russo D; Laezza D; Niccoli G; Burzotta F; Trani C; Mazzari MA; Mongiardo R; Rebuzzi AG; Crea F
    JACC Cardiovasc Interv; 2012 Apr; 5(4):402-8. PubMed ID: 22516396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of intracoronary nicorandil for inducing hyperemia on fractional flow reserve measurement: Comparison with intracoronary papaverine.
    Matsumoto H; Mikuri M; Masaki R; Tanaka H; Ogura K; Arai T; Sakai R; Oishi Y; Okada N; Shinke T
    Int J Cardiol; 2020 Sep; 314():1-6. PubMed ID: 32387252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of Hyperemia With Intracoronary Administration of Papaverine.
    Mizukami T; Sonck J; Gallinoro E; Kodeboina M; Canvedra A; Nagumo S; Bartunek J; Wyffels E; Vanderheyden M; Shinke T; De Bruyne B; Collet C
    J Am Heart Assoc; 2021 Feb; 10(3):e018562. PubMed ID: 33459027
    [No Abstract]   [Full Text] [Related]  

  • 20. Sinus Standstill in a Patient after Intracoronary Papaverine Administration for a Coronary Fractional Flow Reserve.
    Nauchi M; Sakai T; Yamawaki M; Ito Y
    Int Heart J; 2018 May; 59(3):630-633. PubMed ID: 29681575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.